Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion type Assertion NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_head.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion wasGeneratedBy ECO_0000203 NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_provenance.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion wasDerivedFrom befree-20150227 NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_provenance.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion SIO_000772 24577808 NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_provenance.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion evidence source_evidence_literature NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_provenance.
- NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_assertion description "[Although clinical trials have been performed with anti-IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496327.RAz_hVDCARAHG4JPet0HtafGOcuXWW6o9nozyOhKgnCis130_provenance.